Artivion (NYSE:AORT) today announced positive results from a clinical trial for its On-X mechanical mitral valve replacement (MVR). Atlanta-based Artivion (formerly CryoLife) published results in The Annals of Thoracic Surgery. The Proact clinical trial, a multicenter, non-inferiority, two-arm study assessed whether, after an On-X MVR, patients could be safely managed with lower-intensity warfarin plus aspirin. […]
CryoLife
CryoLife announces corporate rebrand, changes name to Artivion
CryoLife today announced that it is rebranding itself and changing its name to Artivion, effective immediately. The Kennesaw, Georgia-based company’s new name, derived from the words ‘aorta,’ ‘innovation’ and ‘vision,’ reflects its focus on creating devices to treat aortic disease. The company will also change its ticker symbol on the New York Stock Exchange to […]
CryoLife buys Ascyrus Medical
CryoLife (NYSE:CRY) announced today that it will acquire Ascyrus Medical and its Ascyrus Medical Dissection Stent. The financial terms of the deal were not disclosed. AMDS is an aortic arch remodeling device used for the treatment of acute type A aortic dissections. The acquisition will strengthen CryoLife’s position in the growing aortic repair market, according to […]
CryoLife prices $100m offering
CryoLife Inc. (NYSE:CRY) announced today that it priced its previously announced offering of convertible senior notes at $100 million. Yesterday, the Atlanta-based company said it is offering the 4.25% notes, due in 2025, as well as a 13-day option for the initial purchaser to buy up to an additional $15 million in notes, which will be […]
CryoLife announces $100m offering
CryoLife Inc. (NYSE:CRY) announced today that it intends to offer a private placement of convertible senior notes worth $100 million. The Atlanta-based company is offering the notes, due in 2025, as well as a 13-day option for initial purchasers to buy up to an additional $15 million in notes, which will be senior unsecured obligations of […]
15 heart devices that could boost their manufacturers’ sales
Before the coronavirus pandemic hit, medtech companies large and small were making notable news with a number of innovative heart devices. Some of these same companies took a big hit to their bottom lines when the danger of spreading COVID-19 and using up precious personal protective equipment convinced hospitals to limit non-urgent procedures. Now hospitals […]
CryoLife wins CE mark for E-vita Open NEO stent graft system
CryoLife Inc. (NYSE:CRY) this week said it won CE mark approval for the E-vita Open NEO hybrid stent graft system to treat aortic arch disease. The hybrid stent graft technologies allow for a one-stage procedure treatment of this condition by combining the surgical arch repair and endovascular descending thoracic repair. “We are pleased to have received […]
CryoLife wins CE Mark for ascending aortic prosthesis
CryoLife Inc. (NYSE:CRY) announced that it received CE Mark approval for the On-X ascending aortic prosthesis (AAP) for treating native or prosthetic heart valves in the aortic position involving an ascending aortic aneurysm. The approval allows for resumed distribution of the On-X AAP in Europe, as the product has been off the market there since late […]
CryoLife to begin investigational trial on using aortic valve without warfarin
CryoLife Inc. (NYSE:CRY) announced that it had its investigational new drug application accepted by the FDA for a clinical trial to observe whether the On-X mechanical aortic valve can be maintained on apixaban instead of warfarin. The On-X aortic valve is the first mechanical aortic heart valve to win FDA and CE Mark approval for labeling […]
CryoLife, Misonix sign distribution deal for NeoPatch
CryoLife this week said it signed a distribution agreement with Misonix where Misonix will have exclusive commercialization rights of NeoPatch. The NeoPatch, made by CryoLife, is a dehydrated and terminally sterilized chorioamniotic allograft that is made from human placental membrane. It is designed to treat a wide range of indications outside of cardiac and vascular […]
CryoLife wins CE Mark for E-nya thoracic stent graft
CryoLife Inc. (NYSE:CRY) announced that it received CE Mark approval for its E-nya thoracic stent graft system for minimally invasive procedures intended to repair lesions of the descending thoracic aorta, including thoracic aortic aneurysms and dissections. In December 2017, CryoLife completed the $225 million acquisition of German stent graft and surgical graft maker Jotec. Kennesaw, Ga.-based […]
